menu
    • menu
    [{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG142","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell Therapy \/ Inapplicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SCG101","moa":"HBsAg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SCG Cell Therapy

    Menu

    SCG Cell Therapy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SCG Cell Therapy

                            Singapore arrow
                            IFT FIRST
                            Not Confirmed

                            SCG Cell Therapy

                            Singapore arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCG142

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SCG Cell Therapy Gets FDA IND Clearance for SCG142 HPV-specific TCR T Cell Therapy

                            Details : SCG142, is a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy, being investigated in patients with HPV-associated solid tumors.

                            Product Name : SCG142

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 30, 2024

                            Lead Product(s) : SCG142

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SCG Cell Therapy

                            Singapore arrow
                            IFT FIRST
                            Not Confirmed

                            SCG Cell Therapy

                            Singapore arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SCG101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SCG Cell Therapy Announces U.S FDA Clearance of Investigational New Drug Application for SCG101, SCG's Novel T...

                            Details : SCG101 is an autologous TCR T cell therapy that can recognize HBV-derived T cell epitope presented on the cell surface by specific major histocompatibility complex (MHC) class I molecules.

                            Product Name : SCG101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : SCG101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth